Elan, Transition push ahead with troubled Alzheimer’s drug

Elan and Transition Therapeutics have reported fresh trouble with their partnered Alzheimer's drug, noting that it failed to hit its mid-stage primary endpoints. Late last year the deaths of nine patients in the study prompted investigators to drop the highest dose being used in the trial. But the two developers say they're committed to pushing ahead into Phase III, despite a considerable amount of flak coming from analysts following their progress. Elan reported that the ELND005 study's...